FinancialContent

Articles published by Veracyte, Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation
From Veracyte, Inc.
Via GlobeNewswire
Tickers VCYT
News headline image
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
From Veracyte, Inc.
Via GlobeNewswire
Tickers VCYT
News headline image
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
From Veracyte, Inc.
Via GlobeNewswire
Tickers VCYT
News headline image
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Veracyte, Inc.
Via GlobeNewswire
Tickers VCYT
News headline image
Veracyte Announces Second Quarter 2026 Financial Results
From Veracyte, Inc.
Via GlobeNewswire
Tickers VCYT
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via GlobeNewswire
Tickers VCYT
News headline image
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte Announces First Quarter 2026 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte Names Kevin Haas as Chief Development and Technology Officer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte Announces Third Quarter 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
News headline image
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
< Previous 1 2 3 4 5 6 Next >